Area of Technology:Life Sciences
Title of the Innovation: Novel Cationic 17-Estradiol-Substituted-Estradiol Derivatives with Anti-Cancer Activity
Brief About Innovation
Brief: Tested preclinically in triple negative breast tumor animal model (the most aggressive breast cancer model). The molecule is co-formulated in liposomes and developed further in association with Mayo Clinic, USA for treating multiple other aggressive cancers such as melanoma, pancreatic cancer.
Beta Version
Copyright © 2023. NRDC - All Rights Reserved
Designed and Developed by Maxtra Technologies.
